Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	1.27B
Revenue (ttm)	246.03M
Net Income (ttm)	-32.00M
Shares Out	161.48M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	55.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,547,528
Open	7.92
Previous Close	7.89
Day's Range	7.75 - 7.96
52-Week Range	2.48 - 8.03
Beta	0.91
Analysts	Strong Buy
Price Target	8.00 (+1.91%)
Earnings Date	Nov 7, 2025

About XERS

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 394
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS
• Website: https://www.xerispharma.com

Financial Performance

In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 1.91% from the latest price.

Price Target

$8.0

(1.91% upside)

Analyst Consensus: Strong Buy